Lupin Settles $90 Million Patent Dispute with Astellas to Secure Mirabegron Market Access
Key Insights
Lupin has settled a patent infringement dispute with Astellas Pharma for $90 million, allowing continued sales of generic Mirabegron in the U.S. market.
The settlement includes a $75 million prepaid option payment and per-unit license fees through September 2027, resolving litigation that began after Lupin's 2024 FDA approval.
Mirabegron holds approximately 26-27.6% of the overactive bladder (search) treatment market, which was valued at $3.63 billion in 2023.
Generic pharmaceutical manufacturer Lupin has reached a $90 million settlement with Astellas Pharma to resolve a patent infringement dispute over the overactive bladder (search) drug Mirabegron, securing the Indian company's continued access to the lucrative U.S. market. The agreement, announced in a February 10, 2026 filing, allows Lupin and its wholly owned U.S. subsidiary Lupin Pharmaceuticals Inc. (search) to continue selling their generic version of the medication.
Settlement Terms and Financial Impact
Under the confidential agreement, Lupin will pay Astellas $90 million, comprising a $75 million prepaid option payment and additional per-unit license fees for each unit sold through September 2027. This substantial financial commitment represents a strategic investment to maintain market access for a product that generated estimated annual U.S. sales of $1.019 billion according to industry data cited by Lupin.
The settlement averts the potential costs and uncertainties of prolonged litigation, which can run into millions of dollars for each party. For Lupin, with a market capitalization approaching ₹100,387 crore, the company appears positioned to absorb this cost given its demonstrated robust financial performance and year-on-year profit growth in recent fiscal quarters.
Legal Background and Market Entry
The dispute originated after Lupin launched Mirabegron Extended-Release Tablets, 25 mg in April 2024, following FDA approval for its generic equivalent of Astellas' Myrbetriq Extended-Release Tablets. Astellas subsequently filed a patent infringement case, and in April 2025, the United States District Court for the District of Delaware ruled in favor of Astellas regarding patent validity. The court had scheduled a consolidated jury trial for 2026 to address infringement issues and damages before the settlement was reached.
Strategic Market Position
Mirabegron occupies a dominant position in the overactive bladder (search) treatment market, capturing approximately 26-27.6% market share due to its favorable safety profile compared to traditional anticholinergics. The overall OAB treatment market was valued at approximately $3.63 billion in 2023 and is projected to continue growing.
For Lupin, maintaining access to the U.S. market is particularly crucial, as the United States contributed around 65% of global Mirabegron sales in 2021. The settlement enables the company to compete effectively against both Astellas and other potential generic manufacturers in a therapeutic segment where patient compliance and efficacy are critical drivers.
Financial Implications and Market Outlook
While the $90 million settlement represents a significant upfront investment that will impact near-term margins, analysts maintain positive outlooks on Lupin with 'Outperform' or 'Moderate Buy' consensus ratings and average price targets around ₹2,306 to ₹2,600. The company's P/E ratio of approximately 23 suggests investor confidence in its earnings capacity.
For Astellas Pharma, with a market capitalization around $28.77 billion, the settlement provides significant cash inflow and resolution, allowing the company to focus resources on its product pipeline and other revenue streams while maintaining some ongoing revenue through the licensing arrangement.